Overtime Granted: Evofem to File Quarterly Report on Form 10-Q for Q3 2022.

Evofem Biosciences, Inc. (OTCQB: EVFM) has been granted an extension by the OTC Markets Group to submit its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022. Originally given until December 29, 2022 to submit the 10-Q, the new deadline is now set for January 6, 2023.

About Evofem

Evofem Biosciences, Inc. is revolutionizing women’s sexual and reproductive health with their FDA-approved product, Phexxi┬«! This revolutionary hormone-free, on-demand prescription contraceptive vaginal gel comes in a box of 12 pre-filled applicators and can be applied 0-60 minutes before each act of sex. With this innovative product, Evofem is helping women take control of their sexual health and well-being.

About Phexxi

Tired of the hassle of taking daily birth control pills? Phexxi is here to help! Phexxi is an on-demand birth control method that prevents pregnancy without the need for a daily routine. It’s easy to use and effective at preventing pregnancy, as long as it’s taken before having sex. Get the facts on Phexxi and learn more about this revolutionary birth control option by speaking with your healthcare provider.

Leave a Comment